Search

Your search keyword '"Constans J."' showing total 1,599 results
Start Over Author "Constans J."
1,599 results on '"Constans J."'

2. COVID-19 Neurologic Complication with CNS Vasculitis-Like Pattern.

Author

Hanafi, R, Roger, P-A, Perin, B, Kuchcinski, G, Deleval, N, Dallery, F, Michel, D, Pruvo, J-P, Outteryck, O, Constans, J-M, and Hacein-Bey, Lotfi

Subjects
Aged, Betacoronavirus, COVID-19, Coronavirus Infections, Humans, Magnetic Resonance Imaging, Male, Multimodal Imaging, Pandemics, Pneumonia, Viral, SARS-CoV-2, Tomography, X-Ray Computed, Vasculitis, Central Nervous System
Abstract

Coronavirus disease 2019 (COVID-19) is a viral infection caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), which spreads rapidly from person to person and manifests in most symptomatic patients as a respiratory illness, similar to prior SARS viruses. Neurologic manifestations of COVID-19 are uncommon; those so far reported include encephalopathy, stroke from large-vessel occlusion, and polyneuropathy. We report a unique neurologic complication of COVID-19 in a patient who had extensive cerebral small-vessel ischemic lesions resembling cerebral vasculitis in a characteristic combined imaging pattern of ischemia, hemorrhage, and punctuate postcontrast enhancement. Also, a characteristic lower extremity skin rash was present in our patient. Our observation lends support to the increasingly suspected mechanism of endotheliitis associated with this novel coronavirus.

Published
2020

4. Recommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l’adulte – Version longue

Author

Sanchez, O., Benhamou, Y., Bertoletti, L., Constans, J., Couturaud, F., Delluc, A., Elias, A., Fischer, A.-M., Frappé, P., Gendron, N., Girard, P., Godier, A., Gut-Gobert, C., Laporte, S., Mahé, I., Mauge, L., Meneveau, N., Meyer, G., Mismetti, P., Parent, F., Pernod, G., Quéré, I., Revel, M.-P., Roy, P.-M., Salaün, P.-Y., Smadja, D.M., and Sevestre, M.-A.

Published
2021
Full Text
View/download PDF

6. Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI

Author

Brochet, B., Casey, R., Cotton, F., De Sèze, J., Douek, P., Guillemin, F., Laplaud, D., Lebrun-Frenay, C., Mansuy, L., Moreau, T., Olaiz, J., Pelletier, J., Rigaud-Bully, C., Stankoff, B., Vukusic, S., Marignier, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., Collongues, N., Lubetzki, C., Vermersch, P., Labauge, P., Defer, G., Cohen, M., Fromont, A., Wiertlewsky, S., Berger, E., Clavelou, P., Audoin, B., Giannesini, C., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Créange, A., Camdessanché, J.-P., Faure, J., Maurousset, A., Patry, I., Hankiewicz, K., Pottier, C., Maubeuge, N., Labeyrie, C., Nifle, C., Ameli, R., Anxionnat, R., Attye, A., Bannier, E., Barillot, C., Ben Salem, D., Boncoeur-Martel, M.-P., Bonneville, F., Boutet, C., Brisset, J.-C., Cervenanski, F., Claise, B., Commowick, O., Constans, J.-M., Dardel, P., Desal, H., Dousset, Vincent, Durand-Dubief, F., Ferre, J.-C., Gerardin, E., Glattard, T., Grand, S., Grenier, T., Guillevin, R., Guttmann, C., Krainik, A., Kremer, S., Lion, S., Menjot de Champfleur, N., Mondot, L., Outteryck, O., Pyatigorskaya, N., Pruvo, J.-P., Rabaste, S., Ranjeva, J.-P., Roch, J.-A., Sadik, J.C., Sappey-Marinier, D., Savatovsky, J., Tanguy, J.-Y., Tourbah, A., Tourdias, T., Roca, P., Colas, L., Tucholka, A., Rubini, P., Cackowski, S., Ding, J., Budzik, J.-F., Renard, F., Doyle, S., Barbier, E.L., Bousaid, I., Lassau, N., and Verclytte, S.

Published
2020
Full Text
View/download PDF

7. Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19

Author

Khider, L., Soudet, S., Laneelle, D., Boge, G., Bura-Rivière, A., Constans, J., Dadon, M., Desmurs-Clavel, H., Diard, A., Elias, A., Emmerich, J., Galanaud, J.-P., Giordana, P., Gracia, S., Hamade, A., Jurus, C., Le Hello, C., Long, A., Michon-Pasturel, U., Mirault, T., Miserey, G., Perez-Martin, A., Pernod, G., Quere, I., Sprynger, M., Stephan, D., Wahl, D., Zuily, S., Mahe, G., and Sevestre, M.A.

Published
2020
Full Text
View/download PDF

16. REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

Author

Lévy, C., Allouache, D., Lacroix, J., Dugué, A.E., Supiot, S., Campone, M., Mahe, M., Kichou, S., Leheurteur, M., Hanzen, C., Dieras, V., Kirova, Y., Campana, F., Le Rhun, E., Gras, L., Bachelot, T., Sunyach, M.-P., Hrab, I., Geffrelot, J., Gunzer, K., Constans, J.-M., Grellard, J.-M., Clarisse, B., and Paoletti, X.

Published
2014
Full Text
View/download PDF

19. The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study

Author

Maraveyas, A., Kraaijpoel, N., Bozas, G., Huang, C., Mahe, I., Bertoletti, L., Bartels-Rutten, A., Beyer-Westendorf, J., Constans, J., Iosub, D., Couturaud, F., Munoz, A. J., Biosca, M., Lerede, T., van Es, N., Di Nisio, M., Accassat, S., Aquilanti, S., Assaf, J. D., Baars, J., Beenen, L. F. M., Bergmann, J. F., Caliandro, R., Carrier, M., Confrere, E., Desormais, I., Dublanchet, N., Endig, S., Falanga, A., Falvo, N., Ferrer Perez, A. I., Garcia Escobar, I., Gonzalez Santiago, S., Grange, C., Helfer, H., Kleinjan, A., Lalezari, F., de Magalhaes, E., Marten, S., Martinez del Prado, P., Otten, H. M., Paleiron, N., Perez Ramirez, S., Pinson, M., Piovella, F., Planquette, B., Rickles, F., Russi, I., Rutjes, A. W. S., Salgado Fernandez, M., Sanchez, O., Sevestre, M. A., Schmidt, J., Thaler, J., Torres Perez-Solero, G., Tromeur, C., Zumarraga Cuesta, A., Graduate School, Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, ARD - Amsterdam Reproduction and Development, Radiology and Nuclear Medicine, ACS - Microcirculation, ANS - Neurovascular Disorders, and Medical Biology

Subjects
medicine.medical_specialty, ECOG Performance Status, Clinical prediction rule, Logistic regression, Risk Assessment, Cohort Studies, cancer associated thrombosis, clinical prediction rule, Risk Factors, Neoplasms, Internal medicine, medicine, Humans, unsuspected pulmonary embolism, Prospective Studies, incidental pulmonary embolism, Retrospective Studies, Performance status, business.industry, risk assessment model, Hematology, Prognosis, medicine.disease, Pulmonary embolism, Cohort, Ambulatory, Pulmonary Embolism, business, Cohort study
Abstract

Background Optimal risk stratification of unsuspected pulmonary embolism (UPE) in ambulatory cancer patients (ACPs) remains unclear. Existing clinical predictive rules (CPRs) are derived from retrospective databases and have limitations. The UPE registry is a prospective international registry with pre-specified characteristics of ACPs with a recent UPE. The aim of this study was to assess the utility of risk factors captured in the UPE registry in predicting proximate (30-, 90- and 180-day) mortality and how they performed when applied to an existing CPR. Objectives To evaluate risk factors for proximate mortality, overall survival, recurrent venous thromboembolism and major bleeding, in the patients enrolled in the UPE registry cohort. Methods Data from the 695 ACPs in this registry were subjected to multivariate logistic regression analyses to identify predictors independently associated with proximate mortality and overall survival. The most consistent predictors were applied to the Hull CPR, an existing 5-point prediction rule. Results The most consistent predictors of mortality were patient-reported respiratory symptoms within 14 days before, and ECOG performance status at the time of UPE. These predictors applied to the Hull-CPR produced a consistent correlation with proximate mortality and overall survival (area under the curve [AUC] = 0.70 [95% CI 0.63, 077], AUC = 0.65 [95% CI 0.60, 070], AUC = 0.64 [95% CI 0.59, 068], and AUC = 0.61, 95% CI 0.57, 0.65, respectively). Conclusion In ACPs with UPE, ECOG performance status logged contemporaneously to the UPE diagnosis and respiratory symptoms prior to UPE diagnosis can stratify mortality risk. When applied to the HULL-CPR these risk predictors confirmed the risk stratification clusters of low-intermediate and high-risk for proximate mortality as seen in the original derivation cohort.

Published
2021

24. Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: An international prospective cohort study

Author

Kraaijpoel, Noémie, Bleker, Suzanne M., Meyer, Guy, Mahé, Isabelle, Muñoz, Andrés, Bertoletti, Laurent, Bartels-Rutten, Annemarieke, Beyer-Westendorf, Jan, Porreca, Ettore, Boulon, Carine, van Es, Nick, Iosub, Diana I., Couturaud, Francis, Biosca, Mercedes, Lerede, Teresa, Lacroix, Philippe, Maraveyas, Anthony, Aggarwal, Anita, Girard, Philippe, Büller, Harry R., di Nisio, Marcello, Accassat, S., Aquilant, S., Assaf, J. D., Baars, J., Beenen, L. M., Bergmann, J. F., Bozas, G., Caliandro, R., Carrier, M., Confrere, E., Constans, J., Désormais, I., Dublanchet, N., Endig, S., Falanga, A., Falvo, N., Ferrer Pérez, Al, García Escobar, I., Gonzàlez Santiago, S., Grange, C., Helfer, H., Kleinjan, A., Lalezari, F., de Magalhaes, E., Marten, S., Martinez del Prado, P., Otten, H. M., Paleiron, N., Pérez Ramírez, S., ACS - Pulmonary hypertension & thrombosis, Vascular Medicine, and ARD - Amsterdam Reproduction and Development

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Incidence (epidemiology), Cancer, 030204 cardiovascular system & hematology, medicine.disease, Pulmonary embolism, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, Cumulative incidence, Clinical significance, Lung cancer, Prospective cohort study, business, Cohort study
Abstract

PURPOSE Pulmonary embolism is incidentally diagnosed in up to 5% of patients with cancer on routine imaging scans. The clinical relevance and optimal therapy for incidental pulmonary embolism, particularly distal clots, is unclear. The aim of the current study was to assess current treatment strategies and the long-term clinical outcomes of incidentally detected pulmonary embolism in patients with cancer. PATIENTS AND METHODS We conducted an international, prospective, observational cohort study between October 22, 2012, and December 31, 2017. Unselected adults with active cancer and a recent diagnosis of incidental pulmonary embolism were eligible. Outcomes were recurrent venous thromboembolism, major bleeding, and all-cause mortality during 12 months of follow-up. Outcome events were centrally adjudicated. RESULTS A total of 695 patients were included. Mean age was 66 years and 58% of patients were male. Most frequent cancer types were colorectal (21%) and lung cancer (15%). Anticoagulant therapy was initiated in 675 patients (97%), of whom 600 (89%) were treated with low-molecular-weight heparin. Recurrent venous thromboembolism occurred in 41 patients (12-month cumulative incidence, 6.0%; 95% CI, 4.4% to 8.1%), major bleeding in 39 patients (12-month cumulative incidence, 5.7%; 95% CI, 4.1% to 7.7%), and 283 patients died (12-month cumulative incidence, 43%; 95% CI, 39% to 46%). The 12-month incidence of recurrent venous thromboembolism was 6.4% in those with subsegmental pulmonary embolism compared with 6.0% in those with more proximal pulmonary embolism (subdistribution hazard ratio, 1.1; 95% CI, 0.37 to 2.9; P = .93). CONCLUSION In patients with cancer with incidental pulmonary embolism, risk of recurrent venous thromboembolism is significant despite anticoagulant treatment. Patients with subsegmental pulmonary embolism seemed to have a risk of recurrent venous thromboembolism comparable to that of patients with more proximal clots.

Published
2019

28. Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study

Author

Kremer, S. (Stéphane), Boulay, C. (Clotilde), de Sèze, J. (Jérome), Ferré, J. (Jean-Christophe), Maamar, A. (Adel), Carsin-Nicol, B. (Béatrice), Collange, O. (Olivier), Bonneville, F. (Fabrice), Adam, G. (Gilles), Martin-Blondel, G. (Guillaume), Rafiq, M. (Marie), Geeraerts, T. (Thomas), Delamarre, L. (Louis), Grand, S. (Sylvie), Krainik, A. (Alexandre), Kremer, S. (Stephane), Alleg, M. (Manel), Anheim, M. (Mathieu), Anxionnat, R. (René), Ardellier, F. (François-Daniel), Baloglu, S. (Seyyid), Bapst, B. (Blanche), Benzakoun, J. (Joseph), Berge, J. (Jérome), Bolognini, F. (Federico), Bornet, G. (Grégoire), Boulouis, G. (Grégoire), Boutet, C. (Claire), Brisset, J. (Jean Christophe), Caillard-ohlmann, S. (Sophie), Carré, S. (Sophie), Comby, P. (Pierre-Olivier), Constans, J. (Jean Marc), David, J. (Jean-Stéphane), de Beaurepaire, I. (Isaure), De Seze, J. (Jerome), Desal, H. (Hubert), Edjlali-Goujon, M. (Myriam), Fabre, X. (Xavier), Fafi-Kremer, S. (Samira), Feuerstein, P. (Philippe), Henry Feugeas, M. (Marie-Cécile), Forestier, G. (Géraud), Gaudemer, A. (Augustin), Hansmann, Y. (Yves), Heintz, A. (Adrien), Boisrame, J. (Julie), Hemmert, C. (Céline), Hmeydia, G. (Ghazi), Jager, L. (Lavinia), Kazémi, A. (Apolline), Kerleroux, B. (Basile), Khalil, A. (Antoine), Lacalm, A. (Audrey), Lecler, A. (Augustin), Lecocq, C. (Claire), Lefebvre, N. (Nicolas), Lersy, F. (François), Matthieu, M. (Muriel), Megdiche, I. (Imen), Mertes, P. (Paul-michel), Messié, J. (Julien), Metanbou, S. (Serge), Meyer, N. (Nicolas), Meziani, F. (Ferhat), Mutschler, V. (Veronique), Nesser, P. (Patrick), Oesterlé, H. (Hélène), Ohana, M. (Mickaël), Oppenheim, C. (Catherine), Pyatigorskaya, N. (Nadya), Ricolfi, F. (Frédéric), Saleme, S. (Suzana), Schenck, M. (Maleka), Schmitt, E. (Emmanuelle), Schneider, F. (Francis), Sebag, N. (Nathan), Talla Mba, Y. (Yannick), Thouant, P. (Pierre), Willaume, T. (Thibault), Zhu, F. (François), Zorn, P. (Pierre-Emmanuel), Cotton, F. (François), Les Hôpitaux Universitaires de Strasbourg (HUS), Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Radiologie [CHU de Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], CHU Toulouse [Toulouse], CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre hospitalier de Haguenau, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nancy (CHU Nancy), CHU Henri Mondor, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), CHU Bordeaux [Bordeaux], Hôpitaux Civils de Colmar, Hôpital Privé d'Antony, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Observatoire Français de la Sclérose En Plaques [Lyon] (OFSEP), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Amiens-Picardie, Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier de Roanne (CH Roanne), CH de Roanne, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Limoges, CHU Strasbourg, Nouvel Hôpital Civil de Strasbourg, Université de Strasbourg (UNISTRA), Hôpital Marie-Madeleine [Forbach], CHU Lille, Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Les Hôptaux universitaires de Strasbourg (HUS), Nanomédecine Régénérative (NanoRegMed), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Henri Mondor [Créteil], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Ferré, Jean-Christophe, and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, Male, medicine.medical_specialty, Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC], Adolescent, Pneumonia, Viral, Gastroenterology, 030218 nuclear medicine & medical imaging, Temporal lobe, White matter, Cohort Studies, 03 medical and health sciences, symbols.namesake, Betacoronavirus, Young Adult, 0302 clinical medicine, Cerebrospinal fluid, Internal medicine, Intensive care, medicine, Humans, Radiology, Nuclear Medicine and imaging, 10. No inequality, Child, Pandemics, Fisher's exact test, Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, SARS-CoV-2, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.NEUR] Cognitive science/Neuroscience, Brain, COVID-19, Retrospective cohort study, Magnetic resonance imaging, Middle Aged, medicine.disease, Magnetic Resonance Imaging, 3. Good health, Venous thrombosis, medicine.anatomical_structure, Neuroradiology, 030220 oncology & carcinogenesis, symbols, Female, business, Coronavirus Infections
Abstract

International audience; BackgroundBrain MRI parenchymal signal abnormalities have been associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).PurposeTo describe the neuroimaging findings (excluding ischemic infarcts) in patients with severe coronavirus disease 2019 (COVID-19) infection.Materials and MethodsThis was a retrospective study of patients evaluated from March 23, 2020, to April 27, 2020, at 16 hospitals. Inclusion criteria were (a) positive nasopharyngeal or lower respiratory tract reverse transcriptase polymerase chain reaction assays, (b) severe COVID-19 infection defined as a requirement for hospitalization and oxygen therapy, (c) neurologic manifestations, and (d) abnormal brain MRI findings. Exclusion criteria were patients with missing or noncontributory data regarding brain MRI or brain MRI showing ischemic infarcts, cerebral venous thrombosis, or chronic lesions unrelated to the current event. Categorical data were compared using the Fisher exact test. Quantitative data were compared using the Student t test or Wilcoxon test. P < .05 represented a significant difference.ResultsThirty men (81%) and seven women (19%) met the inclusion criteria, with a mean age of 61 years ± 12 (standard deviation) (age range, 8–78 years). The most common neurologic manifestations were alteration of consciousness (27 of 37, 73%), abnormal wakefulness when sedation was stopped (15 of 37, 41%), confusion (12 of 37, 32%), and agitation (seven of 37, 19%). The most frequent MRI findings were signal abnormalities located in the medial temporal lobe in 16 of 37 patients (43%; 95% confidence interval [CI]: 27%, 59%), nonconfluent multifocal white matter hyperintense lesions seen with fluid-attenuated inversion recovery and diffusion-weighted sequences with variable enhancement, with associated hemorrhagic lesions in 11 of 37 patients (30%; 95% CI: 15%, 45%), and extensive and isolated white matter microhemorrhages in nine of 37 patients (24%; 95% CI: 10%, 38%). A majority of patients (20 of 37, 54%) had intracerebral hemorrhagic lesions with a more severe clinical presentation and a higher admission rate in intensive care units (20 of 20 patients [100%] vs 12 of 17 patients without hemorrhage [71%], P = .01) and development of the acute respiratory distress syndrome (20 of 20 patients [100%] vs 11 of 17 patients [65%], P = .005). Only one patient had SARS-CoV-2 RNA in the cerebrospinal fluid.ConclusionPatients with severe coronavirus disease 2019 and without ischemic infarcts had a wide range of neurologic manifestations that were associated with abnormal brain MRI scans. Eight distinctive neuroradiologic patterns were described.

Published
2020

29. A novel rare c. -39C>T mutation in the PROS1 5’UTR causing PS deficiency by creating a new upstream translation initiation codon and inhibiting the production of the natural protein

Author

Anne Boland, Omar Soukarieh, Mouton C, Robert Olaso, Pierre Morange, Maguelonne Roux, David A. Tregouet, Carole Proust, Jean-François Deleuze, Sylvie Labrouche-Colomer, Constans J, Béatrice Jaspard-Vinassa, Céline Besse, and Huguenin Y

Subjects
Genetics, Whole genome sequencing, Sanger sequencing, 0303 health sciences, Mutation, Five prime untranslated region, PROS1 Gene, 030204 cardiovascular system & hematology, Biology, medicine.disease_cause, 03 medical and health sciences, Exon, symbols.namesake, 0302 clinical medicine, Eukaryotic translation, medicine, symbols, Coding region, 030304 developmental biology
Abstract

SummaryInherited Protein S deficiency (PSD) (MIM176880) is a rare automosal dominant disorder caused by rare mutations, mainly located in the coding sequence of the structuralPROS1gene, and associated with an increased risk of venous thromboembolism. To identify the molecular defect underlying PSD observed in an extended French pedigree with 7 PSD affected members in who no candidate deleteriousPROS1mutation was detected by Sanger sequencing ofPROS1exons and their flanking intronic regions or via a MLPA approach, a whole genome sequencing strategy was adopted. This led to the identification of a never reported C to T substitution at c.-39 from the natural ATG codon of thePROS1gene that completely segregates with PSD in the whole family. This substitution ACG->ATG creates a new start codon upstream of the main ATG. We experimentally demonstrated that the variant generates a novel overlapping ORF and inhibits the translation of the wild type protein from the main ORF in HeLa cells. This work describes the first example of 5’UTRPROS1mutation causing PSD through the creation of an upstream ORF, a mutation that is not predicted to be deleterious by standard annotation softwares.

Published
2020
Full Text
View/download PDF

30. Role of flow magnetic resonance imaging in the monitoring of facial allotransplantations: preliminary results on graft vasculopathy.

Author

UCL - SSS/IREC/MORF - Pôle de Morphologie, UCL - (SLuc) Service de chirurgie plastique, Bettoni, J, Balédent, O, Petruzzo, P, Duisit, Jérôme, Kanitakis, J, Devauchelle, B, Lengelé, Benoît, Constans, J-M, Morelon, E, Dakpé, S, UCL - SSS/IREC/MORF - Pôle de Morphologie, UCL - (SLuc) Service de chirurgie plastique, Bettoni, J, Balédent, O, Petruzzo, P, Duisit, Jérôme, Kanitakis, J, Devauchelle, B, Lengelé, Benoît, Constans, J-M, Morelon, E, and Dakpé, S

Abstract

Chronic vascular rejection characterized by the myointimal proliferation of smooth muscle cells that progressively obstruct the arterial graft lumen may become the main cause of long-term graft loss in vascularized composite allotransplantation (VCA), as observed in solid organ transplantation. As such, new diagnostic tools are required. The objective of this study was to evaluate the usefulness of flow magnetic resonance imaging (MRI) in the qualitative and quantitative monitoring of VCA in three patients transplanted between 2005 and 2012. Seven flow MRI acquisitions were performed concurrently with standardized clinical and histological monitoring between 2015 and 2017. A progressive reduction in the average flow rate and intraluminal diameter of the arterial pedicle of the grafts was demonstrated. During follow-up, two patients developed chronic vascular rejection requiring partial resection of the graft. For these patients, flow MRI acquisitions were characterized by a significant reduction in vascular signal, with a reduction in intravascular flow prior to anatomical injury. The results of this study confirm the feasibility of reproducible, non-invasive, and non-operator-dependent morphometric and haemodynamic radiological analysis, providing clinicians with new information on the vascular status of VCA over time and offering the prospect of an imaging technique specific to vascular outflow.

Published
2020

44. New rare variants and interpretation of the genetic diversity at the group-specific component (GC) locus in populations in India

Author

Mastana, S.S., Constans, J., and Papiha, S.S.

Subjects
India -- Demographic aspects, Human population genetics -- Analysis, Biological sciences, Analysis, Demographic aspects
Abstract

S.S. MASTANA,(1) J. CONSTANS,(2) AND S.S. PAPIHA(3) Abstract As part of our ongoing genetic studies, 2635 samples from 30 populations of the Indian subcontinent have been analyzed for GC subtype [...]

Published
1996

48. CO9.2 - Développement d'un modèle de prédiction avec données de survie en présence de risques concurrents : exemple de la prédiction du risque d’événement vasculaire chez des patients suspects d'ischémie critique chronique des membres inférieurs

Author

Asselineau, J., Constans, J., Boulon, C., and Lhomme, E.

Abstract

L'ischémie critique chronique des membres inférieurs (ICCMI) est généralement causée par une artériopathie oblitérante des membres inférieurs et peut mener à une amputation majeure du membre inférieur ou au décès de cause vasculaire. Prédire le risque de ces événements vasculaires majeurs aurait un grand intérêt pour décider une revascularisation, souvent très délicate. L'objectif de ce travail était de développer un modèle de prédiction de survenue d'un événement vasculaire majeur dans l'année suivant la suspicion d'ICCMI, à partir de deux classifications d'ICCMI, de facteurs cliniques ou hémodynamiques, en tenant compte des défis statistiques liés aux données de survie avec présence de risques concurrents.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results